Bio-Rad Laboratories (BIO) | Stock Overview & Key Data
Bio-Rad Laboratories Performance Comparison
Stock Range
Today's Range
Low: $285.10
High: $289.75
on August 15, 2025
52 Week Range
Low: $211.43
High: $387.99
on June 3, 2025
on November 6, 2024
All-Time High: $832.70 on August 30, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$7.4B
EPS
11.08
P/E Ratio (TTM)
24.80
Forward P/E
23.58
P/B Ratio
1.04
PEG Ratio
23.58
Div. Yield
N/A
ROE
4.59%
Beta
0.906
Debt to Equity
19.73
Financial Highlights
Profitability
Gross Margin
52.99%
Operating Margin
12.19%
Profit Margin
12.50%
Returns and Earnings
Return on Assets (TTM)
1.59%
Return on Equity (TTM)
4.59%
EBITDA
$463.0M
Net Income (TTM)
$319.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$91.19
Quarterly Revenue Growth (YoY)
2.10%
Quarterly Earnings Growth (YoY)
2.06%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories BIO | 7.40B Mid-cap | 8.12% | 15.49% | 17.46% | 0.87% | -12.42% | -12.26% | -44.01% | -44.85% |
| Abbott Laboratories ABT | 228.04B Mega-cap | -1.88% | 0.20% | -1.20% | 1.21% | 16.14% | 18.69% | 19.71% | 28.66% |
| Boston Scientific BSX | 152.25B Large-cap | 0.03% | -0.30% | -1.61% | -2.07% | 15.43% | 31.85% | 145.53% | 168.46% |
| Penumbra PEN | 9.69B Mid-cap | 5.21% | 7.03% | -8.10% | -6.68% | 5.43% | 32.81% | 55.73% | 8.75% |
| Globus Medical GMED | 8.36B Mid-cap | 3.27% | 8.41% | 4.76% | -28.60% | -25.98% | -13.30% | -6.53% | 13.36% |
| Masimo MASI | 8.16B Mid-cap | 6.32% | -3.86% | -0.34% | -14.69% | -8.72% | 24.66% | -1.19% | -29.80% |
Ownership & Short Interest
Insider Ownership
16.19%
Institutional Ownership
93.21%
Shares Short
917K
Short Ratio
3.32
Short % of Shares Outstanding
4.76%
Average 10-Day Volume
394K
Average 90-Day Volume
304K
Bio-Rad Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Bio-Rad Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIO's 52-week high and low?
- In the last 52 weeks, Bio-Rad Laboratories reached a high of $387.99 (on November 6, 2024) and a low of $211.43 (on June 3, 2025).
- What is the market cap and P/E ratio for BIO?
- Curious about Bio-Rad Laboratories's size and valuation? Its market capitalization stands at 7.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is 24.80, and the forward P/E (looking ahead) is 23.58.
- Does BIO pay dividends? If so, what's the yield?
- As for dividends, Bio-Rad Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bio-Rad Laboratories's main competitors or similar companies to consider before investing?
When looking at Bio-Rad Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT228.04B Healthcare Medical Devices 18.69% 19.71% Boston Scientific
BSX152.25B Healthcare Medical Devices 31.85% 145.53% Penumbra
PEN9.69B Healthcare Medical Devices 32.81% 55.73% Globus Medical
GMED8.36B Healthcare Medical Devices -13.30% -6.53% Masimo
MASI8.16B Healthcare Medical Devices 24.66% -1.19% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bio-Rad Laboratories Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Bio-Rad Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.59%, the Debt to Equity ratio from the most recent quarter is 19.73, and its Gross Profit Margin stands at 52.99%.
- What is the recent revenue and earnings growth for BIO?
- Looking at Bio-Rad Laboratories's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.10%, and quarterly earnings saw a YoY growth of 2.06%.
- How much of BIO stock is held by insiders and institutions?
- Wondering who owns Bio-Rad Laboratories stock? Company insiders (like executives and directors) hold about 16.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 93.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.